A. ELISA assay. Each well was coated by 50 ng puri?ed in?uenza hemagglutinin H3. 0-100 ng anti-In?uenza A virus Hemagglutinin H3 monoclonal antibody (TCI Product No. : I0779) was added to the well. After washing, bound antibody was detected using goat-anti-mouse IgG-HRP conjugate. The signal was developed with ABTS substrate (TCI Product No. : A2166).
B. Western Blot. Analysis was performed using anti-In?uenza A virus Hemagglutinin H3 monoclonal antibody (I0779) at 1 μg/ml. Goat-anti-mouse-HRP conjugate was used as the secondary antibody. The signal was visualized using DAB-nickel as the chromogen. Molecular weight marker (M). Puri?ed Hemagglutinin (Lane 1).
Maximum quantity allowed is 999
Please select the quantity
Anti-Influenza Virus Monoclonal Antibodies
_resize.jpg)
Influenza viruses are members of the Orthomyxoviridae family, and as such are enveloped viruses that contain segmented genomes composed of negative-sense, single-stranded RNA1). There are three genera of in?uenza viruses, types A, B and C. Type A in?uenza viruses are grouped into subtypes based on antigenic properties of the viral-encoded hemagglutinin (HA) and neuraminidase (NA) envelope glycoproteins.
Monoclonal antibodies are essential tools for many molecular immunology investigations. Especially, anti-in?uenza virus monoclonal antibodies are useful for diagnosis and investigations of virus structure. These monoclonal antibodies introduced here are suitable for use in ELISA and Western blot.
¦Typical Procedure
Monoclonal antibodies are essential tools for many molecular immunology investigations. Especially, anti-in?uenza virus monoclonal antibodies are useful for diagnosis and investigations of virus structure. These monoclonal antibodies introduced here are suitable for use in ELISA and Western blot.
¦Typical Procedure
Figure. Reactivity of the anti-in?uenza A hemagglutinin monoclonal antibody
A2380 Anti-Influenza A Virus Neuraminidase N2 Monoclonal Antibody
(Preservative : 0.05% NaN3, Stabilizer : 1% BSA)
(This product is unavailable in the U.S. and China.)
| Immunogen | : | Influenza A/sydney/5/97(strain H3N2) | |
| Isotype | : | IgG1 | |
| Host | : | Mouse | |
| Clone | : | 1-4B | |
| Product Form | : | Protein G purified, mouse monoclonal antibody | |
| Preservative | : | 0.05 % NaN3 | |
| Applications | : | ELISA, Western Blot. Not tested in other applications. |
Optimal dilutions are dependent on conditions and should be determined by the user.
A2406 Anti-Influenza A Virus Nucleoprotein Monoclonal Antibody
(Preservative : 0.05% NaN3, Stabilizer : 1% BSA)
(This product is unavailable in the U.S. and China.)
| Immunogen | : | Influenza A/Beijing/262/95 | |
| Isotype | : | IgG2a | |
| Host | : | Mouse | |
| Clone | : | 17 | |
| Product Form | : | Protein G purified, mouse monoclonal antibody | |
| Preservative | : | 0.05 % NaN3 | |
| Applications | : | ELISA, Western Blot. Not tested in other applications. |
Optimal dilutions are dependent on conditions and should be determined by the user.
A2407 Anti-Influenza A Virus Neuraminidase N1 Monoclonal Antibody
(Preservative : 0.05% NaN3, Stabilizer : 1% BSA)
(This product is unavailable in the U.S. and China.)
| Immunogen | : | Influenza A/Beijing/262/95 | |
| Isotype | : | IgG1 | |
| Host | : | Mouse | |
| Clone | : | 2-3B | |
| Product Form | : | Protein G purified, mouse monoclonal antibody | |
| Preservative | : | 0.05 % NaN3 | |
| Applications | : | ELISA, Western Blot. Not tested in other applications. |
Optimal dilutions are dependent on conditions and should be determined by the user.
I0779 Anti-Influenza A Virus Hemagglutinin H3 Monoclonal Antibody
(Preservative : 0.05% NaN3, Stabilizer : 1% BSA)
(This product is unavailable in the U.S. and China.)
| Immunogen | : | purified hemagglutinin H3 (Influenza A/sydney/5/97)5 | |
| Isotype | : | IgG3 | |
| Host | : | Mouse | |
| Clone | : | 1G8 | |
| Product Form | : | Protein G purified, mouse monoclonal antibody | |
| Preservative | : | 0.05 % NaN3 | |
| Applications | : | ELISA, Western Blot. Not tested in other applications. |
Optimal dilutions are dependent on conditions and should be determined by the user.
* These monoclonal antibodies were developed by collaboration with Tokai University.
References
- 1)P. F. Wright, R. G. Webster, Orthomyxoviruses, in Fields Virology, 4th ed., Lippincott Williams & Wilkins, Philadelphia, 2001, vol. 1.
- 2)Details of influenza A sydney/5/97
- a)Phenotypic properties resulting from directed gene segment reassortment between wild-type A/Sydney/5/97 influenza virus and the live attenuated vaccine strain
C. L. Parks, T. Latham, A. Cahill, R. E. O'Neill, C. J. Passarotti, D. A. Buonagurio, T. M. Bechert, G. A. D'Arco, G. Neumann, J. DeStefano, H. E. Arendt, J. Obregon, L. Shutyak, S. Hamm, M. S. Sidhu, T. J. Zamb, S. A. Udem, Virology 2007, 367, 275.
- b)Accumulation of amino acid substitutions promotes irreversible structural changes in the hemagglutinin of human influenza AH3 virus during evolution
K. Nakajima, E. Nobusawa, A. Nagy, S. Nakajima, J. Virol. 2005, 79, 6472. - c)Influenza research database
- a)Phenotypic properties resulting from directed gene segment reassortment between wild-type A/Sydney/5/97 influenza virus and the live attenuated vaccine strain
| Product Number | A2380 |
| CAS RN | |
| Purity / Analysis Method: |
| Product Number | A2406 |
| CAS RN | |
| Purity / Analysis Method: |
| Product Number | A2407 |
| CAS RN | |
| Purity / Analysis Method: |
Product Number: A2380 |
Purity / Analysis Method:
Product Number: A2406 |
Purity / Analysis Method:
Product Number: A2407 |
Purity / Analysis Method:
Added to Your Shopping Cart
Product Availability by Store Location
Hours